Carolina D Schinke MD

PubMed

• Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma.
  Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy Jr, Fenghuang Zhan
  Blood Advances. 2025-05-13
• Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma.
  Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi
  Blood Cancer Journal. 2025-04-23
• Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience.
  Bhavesh Mohan Lal, Toshali Pandey, Marah Alzubi, Jawad Alrawabdeh, John Shaughnessy Jr
  Bone Marrow Transplantation. 2025-04-17

Journal Articles

• Mesenchymal Stem Cells Gene Signature in High‐Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2‐Expressing Small Adipocytes  
  Bart Barlogie, Sharmilan Thanendrarajan, Carolina Schinke, British Journal of Haematology

Abstracts/Posters

• Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Carolina D. Schinke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Mutational Landscape of Primary Plasma Cell Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all